Clinical Trial Update: Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluated nebulised heparin for COVID-19–related acute lung injury and ARDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• Nebulised heparin (heparin)

Snippet

Sponsor: University College Hospital Galway | Conditions: Covid19, ARDS, Human | Phase 1, Phase 2 | Status: COMPLETED